Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on October 31st, 2022% 
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger
By Alan, on October 27th, 2022% 
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
By Alan, on October 26th, 2022% 
Results from a clinical trial show an experimental one-time antibody therapy, even at low doses, lowers levels of HIV virus in people living with the disease. . . . → Read More: Trial Shows Antibody Neutralizes, Reduces HIV Virus
By Alan, on October 25th, 2022% 
A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M
By Alan, on October 24th, 2022% 
A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers
By Alan, on October 20th, 2022% 
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
By Alan, on October 19th, 2022% 
Colorized scanning electron micrograph of a T lymphocyte. (NIAID)
19 Oct. 2022. A biotechnology enterprise discovering new drugs from non-protein coding regions of the genome is raising €37.5 million ($US 36.6 million) in venture funds. Nucleome Therapeutics Ltd. in Oxford, U.K. is a three year-old business spun-off from genetic research labs at University . . . → Read More: “Dark Genome” Drug Discoverer Gains $37M in Early Funds
By Alan, on October 15th, 2022% 
Venture funds for U.S. biotechnology and pharmaceutical start-ups declined in the third quarter of 2022 from the 2021 record pace, but remain on track for historic highs. . . . → Read More: Infographic – US Biotech Venture Funds Fall in Q3
By Alan, on October 14th, 2022% 
A clinical trial is underway testing the safety and chemical activity of a hepatitis-B therapy using engineered RNA to block production of a key protein linked to the disease. . . . → Read More: Trial Begins Testing RNA Hepatitis-B Treatment
By Alan, on October 12th, 2022% 
A new company formed by a technology venture investor and the Mayo Clinic aims to produce and supply more readily available radiation drug therapies. . . . → Read More: Start-Up to Manufacture, Supply Practical Radiation Drugs
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
Comments are closed 
You must be logged in to post a comment.